HighTower Advisors LLC Has $830,000 Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

HighTower Advisors LLC boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 408.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,770 shares of the company’s stock after buying an additional 98,626 shares during the period. HighTower Advisors LLC’s holdings in Recursion Pharmaceuticals were worth $830,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of RXRX. State Street Corp lifted its stake in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the period. Geode Capital Management LLC lifted its stake in Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after buying an additional 656,003 shares during the period. Institute for Wealth Management LLC. bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $3,928,000. Charles Schwab Investment Management Inc. grew its holdings in Recursion Pharmaceuticals by 17.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company’s stock worth $15,372,000 after purchasing an additional 333,323 shares during the period. Finally, Barclays PLC grew its stake in shares of Recursion Pharmaceuticals by 53.9% in the 3rd quarter. Barclays PLC now owns 697,432 shares of the company’s stock valued at $4,596,000 after buying an additional 244,278 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Down 3.2 %

Shares of NASDAQ:RXRX opened at $5.97 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $12.36. The company has a market capitalization of $2.40 billion, a PE ratio of -3.90 and a beta of 0.85. The business has a fifty day moving average price of $7.46 and a two-hundred day moving average price of $7.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s quarterly revenue was down 57.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.42) EPS. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on RXRX. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.